ENDO-ERN expert opinion on the differential diagnosis of pubertal delay by Persani, Luca et al.
Endocrine (2021) 71:681–688
https://doi.org/10.1007/s12020-021-02626-z
CLINICAL MANAGEMENT OF ENDOCRINE DISEASES
ENDO-ERN expert opinion on the differential diagnosis
of pubertal delay
Luca Persani 1,2 ● Marco Bonomi1,2 ● Martine Cools3 ● Mehul Dattani4,5 ● Leo Dunkel6 ● Claus H. Gravholt7,8 ●
Anders Juul9
Received: 30 October 2020 / Accepted: 9 January 2021 / Published online: 29 January 2021
© The Author(s) 2021
Abstract
The differential diagnoses of pubertal delay include hypergonadotropic hypogonadism and congenital hypogonadotropic
hypogonadism (CHH), as well as constitutional delay of growth and puberty (CDGP). Distinguishing between CDGP and
CHH may be challenging, and the scientific community has been struggling to develop diagnostic tests that allow an accurate
differential diagnosis. Indeed, an adequate and timely management is critical in order to enable optimal clinical and
psychosocial outcomes of the different forms of pubertal delays. In this review, we provide an updated insight on the
differential diagnoses of pubertal delay, including the available tests, their meanings and accuracy, as well as some clues to
effectively orientate towards either constitutional pubertal delay or pathologic CHH and hypergonadotropic hypogonadism.
Keywords Hypogonadism ● Pubertal delay ● Constitutional delay of growth and puberty ● Gonadal dysgenesis ● Primary
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Delay of puberty
The process of puberty and its delay
Physiological pubertal development encompasses a
sequential series of pubertal stages, usually occurring
between the age of 8 and 13 years in females, and 9 and 14
years in males. The first signs of pubertal development are
represented by testicular enlargement (testicular volume
>3 mL) in males and breast budding (thelarche) in females.
The appearance of pubic and axillary hair is mainly
dependent upon adrenal androgens and, if isolated, should
not be interpreted as the beginning of gonadotrophin-
dependent puberty [1, 2]. However, in some ethnic popu-
lations pubarche may be the first sign of pubertal onset in a
large proportion of children.
The mechanisms involved in the timing of puberty are
complex and currently not fully understood, but several
intrinsic (e.g. genetic) and environmental cues are involved
in this process [3, 4].
Pubertal delay refers to the absence of the first signs of
pubertal development beyond the normal age distribution
(>2–2.5 standard deviation above the mean of the reference
population) or, when pubertal progress arrests after an initial
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physiological start [5]. A considerable delay in pubertal
onset is associated with significant somatic and psycholo-
gical impact on the adolescent [6].
Causes of delayed puberty
Delay of puberty is very common. Constitutional delay of
growth and puberty (CDGP) is the most frequent form and
is a paraphysiological self-limited condition. Highly vari-
able conditions include the various causes of primary and
central hypogonadism (Table 1).
Hypergonadotropic hypogonadism
In hypergonadotropic hypogonadism the central compart-
ment of the HPG axis activates normally with the onset of
puberty, but the gonads do not respond appropriately due to
an intrinsic gonadal defect. Hypergonadotropic hypogo-
nadism can be differentiated from other forms of pubertal
delay through medical history, physical examination, and
particularly unstimulated reproductive hormone levels,
characterized by low sex steroids and high gonadotropins
(Table 2). Medical and family history should focus on co-
morbidities, e.g. auto-immunity, or previous oncological
treatment. In girls, a prepubertal uterus can be very difficult
to visualize by ultrasound, and caution should be made not
to interpret this as congenital absence of a uterus (e.g. due to
Mayer–Rokitansi syndrome). For this reason, we recom-
mend that these ultrasounds should be conducted and
interpreted by an experienced specialist. Karyotyping may
reveal an atypical sex chromosomal constitution, such as
45,X in a girl or 47,XXY in a boy. More detailed genetic
investigations, mostly by whole exome or genome
sequencing, complement the diagnostic work-up in hyper-
gonadotropic hypogonadism, and may reveal conditions
like differences/disorders of sex development (DSD) or
primary ovarian insufficiency (POI). Genetics underlying
DSD has been reviewed recently [7].
Central hypogonadism
Central or hypogonadotropic hypogonadism includes hor-
monal disturbances that may be due to either organic
(acquired or congenital) or functional (such as chronic ill-
nesses, obsessive focus on food, lifestyle and exercise/
orthorexia, or frank anorexia requiring nutritional rehabili-
tation) conditions that affect either the pituitary and/or the
hypothalamus. Due to the common isolated presentation,
the most frequent differential diagnoses are CDGP and
congenital hypogonadotropic hypogonadism (CHH), which
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olfactory defect, i.e. Kallmann syndrome (KS) [8]. The
pathogenesis of both forms of CHH is still frequently
undefined, although a genetic background can be deter-
mined in ~50% of cases, and the diagnostic yield is likely
to increase in the near future [9, 10].
CDGP refers to a paraphysiological, self-limited form
of delayed puberty that usually represents an extreme of
the normal spectrum of pubertal timing. It is the most
common cause of pubertal delay and in clinical settings
much more common in boys than girls [5]. The sig-
nificant familial recurrence of this defect is indicative of a
strong genetic predisposition. Although the inheritance of
CDGP is variable, an autosomal dominant pattern, in
association with environmental modifiers, has been fre-
quently observed, with a complete or incomplete pene-
trance. So far, no specific causal genes have been
identified to account for the majority of cases of CDGP
[11]. Patients with CDGP may experience slower growth
rate, which results in a lower final adult height [1],
delayed sexual maturation and delayed skeletal age
compared to peers. Usually, the condition has a good
prognosis with full completion of pubertal maturity.
CDGP can be diagnosed only after exclusion of
pathologically absent puberty such as hypergonadotropic
hypogonadism or CHH. However, differentiating
between CDGP and CHH can be extremely challenging
in adolescence. Leaving the diagnosis for later in life,
though easier, may have negative consequences on adult
height, and is frequently the cause of low self-esteem
and behavioral problems and should therefore be
avoided [12].
Once systemic pathologies determining functional HH
are ruled out on clinical examination, the differential
diagnosis between these two conditions is not straight-
forward (Table 2). Adolescents with CHH and CDGP
both have similar clinical features and hormone profiles,
i.e., low gonadotropins (FSH, LH) and sex steroids
(testosterone in males and estradiol in females). Studies
on the discriminatory value of Sertoli cell markers (e.g.,
inhibin B and AMH) or GnRH and hCG stimulation tests
have not proven to be truly reliable [13, 14].
Clinical features
Pubertal delay in males is diagnosed when the testicular
volume, using Prader’s orchidometer, has not reached
4 mL by the age of 14 years [8, 15]. Some characteristic
features may serve as “red flags”, as their presence may
point towards a specific diagnosis or a diagnostic sub-
group (Table 2) [5]. Features of CHH include olfactory
defects, clefting of the palate and/or lips, hearing loss,
alteration of digital bones, colorblindness, nystagmus and
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often present in CHH, so a renal ultrasound should be
included to rule out a morphogenetic defect.
Family history can be positive for delayed puberty in
both CDGP and CHH, even with overlap between the two
conditions within the same family, making the differential
diagnosis even harder [19, 20]. Nevertheless, it is important
to investigate, given the well-documented familial recur-
rence of self-limited pubertal delay or CHH, as well as of its
characteristic-related features (i.e., anosmia, renal mal-
formations, hearing loss, color blindness, etc.).
In boys, the presence of neonatal cryptorchidism (parti-
cularly the bilateral forms) and micropenis are important
findings, pointing to a prenatal and postnatal gonadotropin
deficiency. All boys with an underdeveloped (at least 2.5
SD below the mean) but otherwise normal penis, without
hypospadias, should be further investigated to exclude
CHH, based on baseline assessment of the HPG axis during
minipuberty (~1–4 months after birth), or an HCG stimu-
lation test thereafter, due to the physiological reduction of
gonadotropins until puberty [2, 21]. More complex forms of
genital under-virilization are more likely due to hypergo-
nadotropic hypogonadism rather than CHH [6, 22].
Unfortunately, no specific signs may point to CHH in girls
during the neonatal period and throughout childhood.
Boys and girls with CHH experience normal growth
during childhood, and the absence of long-bone epiphyseal
closure explains their frequent eunuchoid aspect and rela-
tive tallness when diagnosed and thus treatment is delayed.
Retarded bone maturation, osteopenia, and osteoporosis are
often found when the diagnosis of CHH is made later in life
[23, 24].
Short stature with slow growth velocity and low weight
can all point towards functional forms of HH [15] (Table 1).
When these features are mild and syndromic manifestations
are absent, and particularly if there is a positive family
history, the most likely diagnosis is CDGP.
Although in most CHH patients, puberty never occurs,
adult-onset forms of heritable HH exist [25]. These men
typically complain of low libido and erectile dysfunction. In
patients with isolated GnRH deficiency the finding of a
partial progression through puberty followed by a perma-
nent arrest of sexual maturation is not uncommon, which
makes the differentiation between the two conditions even
more difficult [26].
Olfactory defects should be evaluated with a quantitative
olfactory test and/or MRI of the olfactory structures; how-
ever, it should be noted that defects of smell affect <50% of
subjects with CHH. Still, whenever present, olfactory
defects should be considered a reliable clue towards this
diagnosis [27].
Hormones and stimulation tests
An important feature of CHH is the low gonadotropin
concentrations in the pre-pubertal range. However, this
feature alone cannot differentiate between CDGP and CHH
in early adolescence, as gonadotropin concentrations are
frequently bordeline even in healthy subjects (Table 3).
To differentiate between CHH and CDGP, the study of
LH nocturnal pulses has been proposed: in fact, the lack of
nocturnal LH pulses in adolescence was described to be
specific for HH, but a similar pulsatile fluctuation was found
Table 3 Elements for the
differential diagnosis between
CDGP and CHH in males
CDGP CHH
Pubertal delay Yes, but transient Yes, but permanent
Syndromic features Uncommon Common (e.g. anosmia, midline
defects)
Bone age Retarded Retarded
Testo/E2 Low Low
LH/FSH Inappropriately low Inappropriately low




HCG stimulation Normal Testosterone rise Often subnormal testosterone rise
Genetic studies IGSF10 and HS6ST1 monoallelic variants+
wild-type classic CHH genes (ie. GnRHR,
TAC3, TACR3, HS6ST1)






− Testo gel: 10 mg
every 2 days → 1 day
Primed pubertal start:
↑ bi-testicular volume >8 mL
Absent pubertal start:
HH persistence and bi-testicular
volume <8 mL
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in prepubertal children and patients with CDGP and CHH
by using ultrasensitive assays [28]. The only difference
between the two conditions seems to be the absence of
entrainment to nocturnal sleep and the low incidence of
synchronization between LH and FSH pulses [28, 29].
However, the analysis of the nocturnal patterns of gona-
dotropins cannot be used as a diagnostic test in routine
clinical practice.
In order to avoid nocturnal sampling, the diagnostic
utility of a single basal gonadotropin concentration has been
proposed, and a threshold of LH concentrations above
0.2 U/L would indicate onset of puberty [5, 30], but the
accuracy is very low. A similar diagnostic power can be
assigned to the dynamic gonadotropin testing with GnRH or
GnRH analogs. The use of GnRH agonists (GnRHa)
seemed to have a higher discriminatory potential compared
to GnRH for dynamic testing [31]. However, the absence of
a gonadotropin response to GnRH stimulation can confirm
the absence of puberty onset, rather than a true differential
diagnosis between CDGP and CHH (Table 3). The deter-
mination of urinary gonadotropins can be a valuable per-
spective to be validated in this context [32].
Other endocrine markers have been proposed to guide
the differential diagnosis. These include the functional
measurement of Sertoli cells (inhibin B), immature Sertoli
cells (AMH), and Leydig cells (INSL3 and testosterone
after hCG stimulation) [33]. Though promising in certain
cases [31, 34, 35] the available data are insufficient to
clearly identify the potential clinical utility of these markers
mainly due to the overlap of values between CDGP and
CHH. The availability of new methods with higher sensi-
tivity/specificity for their determination may open novel
perspectives (e.g. LC/MS approach).
The measurement of serum AMH concentrations com-
bined with inhibin B has proven to give reassuring results in
cases with a clinical suspicion of pubertal disorders, since
their concentrations reflect the function and number of
Sertoli cells. While these tests cannot discriminate with
guaranteed accuracy between CHH and CDGP they can,
however, be helpful in the early detection of testicular
tubular damage [36].
The testosterone response to a longer-term (19 days)
HCG stimulation test was found to give significantly lower
testosterone levels in CHH, as were the peak serum FSH
responses to GnRH stimulation [37] (Table 3).
However, the combination of several tests is too cum-
bersome and expensive to be used as a first line investiga-
tional approach.
Among the new frontiers of hormonal evaluation, the
responsiveness to the neuropeptide kisspeptin has been
investigated in boys with delayed puberty: Chan Y.M. et al.
hypothesized in 2018 that kisspeptin would stimulate LH
secretion in healthy subjects but not in CHH. At this point,
further studies are needed to see if the kisspeptin stimulation
test in prepubertal children can accurately predict outcomes
for younger boys presenting with delayed puberty, since the
published study included 17 years old patients, and our
main priority is to correctly diagnose correctly the condition
in boys and girls in their young teenage years, around the
onset of physiological puberty [38].
Genetics
To date, 60 genes are known to be associated with the
multiple forms of CHH [9], all of them being genes that
regulate development, migration and secretory function of
GnRH neurons, but there is less knowledge regarding the
genetic background of CDGP (Table 3). However, CDGP
clusters in families [39] and a further study revealed a
degree of overlap between the genetics of CHH and CDGP
[20]. These findings were confirmed in a recent study
describing a somewhat shared genetic predisposition, even
if a greater prevalence of CHH variants and oligogenic
involvement were more typical of CHH patients [40].
Nevertheless, the main utility of contemporary genetic
studies remains its use in family counseling once the
diagnosis is established, rather than as a routine first-
line test.
Priming
Another means to investigate pubertal delay, is the so-called
low dose sex steroid (LDSS) “priming” test (Table 3). Once
partial idiopathic GH deficiency has been excluded as a
possible cause of slow growth rate (normal IGF1 and GH
response to primed stimulation), this option can be proposed
with the intrinsic advantage of also being the treatment of
choice in CDGP. In fact, recent studies have investigated
the diagnostic utility of testosterone priming not only to
treat CDGP, but also to differentiate this condition from
CHH. This is based on the idea that short-term testosterone
treatment (injections, oral, or transdermal) in boys with
CDGP would trigger HPG activation, with enlargement of
the testis and increase in endogenous production of testos-
terone as a result [41]. One of the advantages of this
interventional approach is a shorter delay in the diagnosis
and consequent treatment, since the “diagnostic test” is also
a treatment, with both psychological and physical benefits
on growth rate and virilization. Very recently, a retro-
spective study performed by three ENDO-ERN centers
reported that LDSS priming was associated with a sig-
nificant improvement in final height of CDGP patients [42].
As a result, more expensive tests could be reserved for
those who do not start puberty even after testosterone
priming (i.e. CHH patients) [41]. On the other hand, it has
to be considered that it is currently not known if
Endocrine (2021) 71:681–688 685
testosterone pretreatment prior to gonadotropin therapy
could affect the future fertility potential of male CHH
patients [43–45]. Side effects of testosterone priming
(including acne and in a minority of cases also aggressive
behavior and painful erections) have been shown to be
dose-dependent [46].
In any case, although testosterone priming cannot be
considered an “unsafe” treatment, patients and their family
need to be informed about the connected risks, and most
importantly, in case of priapism a urologist has to be con-
sulted in a timely manner [47].
The same approach has been attempted in females using
low doses of estradiol as a priming therapy. The current
evidence in females, however, is based mostly on girls who
have β-Thalassemia, of whom 60–80% manifest hypogo-
nadotropic hypogonadism, suggesting that the estradiol
priming could be as useful as testosterone priming in the
awakening of the hypothalamo-pituitary axis in CDGP
female patients [48].
The data also suggest that sex steroid priming could
increase the discriminatory power of dynamic tests (such as
gonadotropin or GH stimulation) if given before such tests,
indicating an interesting application of the technique in
terms of the differential diagnosis of CDGP [42].
Conclusions: How can one approach the
differential diagnosis?
From the above it is clear that there is no strong and
unequivocal evidence to guide us in the differential diag-
nosis and management of CDGP and CHH. However,
according to the pathophysiology of these two conditions,
we propose a tentative flow-chart that could lead through
this tangle of tests and approaches (Fig. 1).
First of all, girls and boys with pubertal delay who do not
have any of the typically associated features can be reas-
sured before 13 or 14 years, respectively [8, 48, 49], as
these ages are considered the upper limit of physiological
puberty. If no sign of puberty has emerged at these ages, or
if puberty does not progress appropriately according to
puberty nomograms for girls and boys, respectively
[50, 51], the determination of gonadotropins and bone age
can be useful as a first diagnostic approach. High gonado-
tropins point to a primary gonadal defect and karyotype is a
key step for the definition of these cases. In the case of
gonadotropins that are inappropriately low for the hypo-
gonadal state a significant bone age delay is indicative of a
complete pubertal immaturity and in the absence of parti-
cular phenotypes a CDGP is the most likely condition.
Based on the above reported data and the potential benefits
for psychological wellbeing and final height [42], LDSS
priming should be proposed to promote a jump start of
spontaneous puberty in CDGP after a thorough discussion
with the patient and their parents. Certainly, if differential
diagnoses of CHH or hypergonadotropic hypogonadism are
reached, appropriate steroid or gonadotropin treatment
should be given in a timely manner at ages corresponding to
physiological puberty in order to minimize psychological
and somatic consequences.
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Fig. 1 Diagnostic flow chart for delayed puberty. CDGP constitutional delay of growth and puberty, LDSS low dose sex steroid, HPG axis
hypothalamus–pituitary–gonadal axis, US ultrasound
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